Banco Santander (SAN) 4.21 $SAN
Kroll Bond Rating Agency Publishes Comment on U.S. Banks: Stress Tests & Quantitative Easing
BusinessWire - Tue Jul 05, 12:03PM CDT
Kroll Bond Rating Agency (KBRA) has released a new research report entitled "U.S. Banks: Stress Tests & Quantitative Easing." The report makes the following key points:
SAN: 4.21 (+0.25), DB: 14.10 (+0.80)
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
PR Newswire - Tue Jul 05, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)
Blow to Deutsche Bank, Santander: Fed Rejects Capital Plans
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 1:34PM CDT
The latest stress test results turned out to be continued embarrassments for Deutsche Bank AG (DB) and Banco Santander, S.A. (SAN) as the Federal Reserve objected to the capital plans of their U.S. units once again.
SAN: 4.21 (+0.25), C: 43.44 (+1.15), DB: 14.10 (+0.80), BAC: 13.54 (+0.33)
Statement on Results of the Federal Reserve's Comprehensive Capital Analysis and Review (CCAR)
PR Newswire - Wed Jun 29, 5:12PM CDT
The Board of Governors of the Federal Reserve System (Federal Reserve) disclosed today the results of its Comprehensive Capital Analysis and Review (CCAR). The results show that Santander Holdings USA, Inc.'s (SHUSA) capital ratios would be expected to remain significantly above minimum regulatory requirements under severely adverse economic stress scenarios.
SC: 11.24 (+0.42), SAN: 4.21 (+0.25)
Banco Santander Affirms 2016 Guidance amid Brexit Fallout
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:35AM CDT
Banco Santander does not expect Brexit to have a material impact on its profits in 2016.
SAN: 4.21 (+0.25), BMO: 64.33 (+0.83), V: 77.48 (+0.96), CM: 75.65 (+0.95)
New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire - Thu Jun 23, 6:56AM CDT
New VaxigripTetra(TM) vaccine:
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Watch List for Foreign Money Center Banks Equities -- Banco Santander, Barclays, Lloyds Banking Group, and Credit Suisse Group
PR Newswire - Wed Jun 15, 7:00AM CDT
On Tuesday, June 14, 2016, the NASDAQ Composite ended the trading session at 4,843.55, down 0.10%; the Dow Jones Industrial Average edged 0.33% lower to finish at 17,674.82; and the S&P 500 closed at 2,075.32, down 0.18%. Stock-Callers.com has initiated coverage on the following equities: Banco Santander S.A. (NYSE: SAN), Barclays PLC (NYSE: BCS), Lloyds Banking Group PLC (NYSE: LYG), and Credit Suisse Group A.G. (NYSE: CS). Learn more about these stocks by accessing their free trade alerts at:
BCS: 7.95 (+0.28), SAN: 4.21 (+0.25), CS: 11.07 (+0.31), LYG: 3.02 (+0.15)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
PR Newswire - Wed May 25, 5:50PM CDT
Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 (1 panelist did not vote due to travel) to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Santander Celebrates Branch Relocation To Union Square Area With Non-Profit Donation And Ribbon Cutting
PR Newswire - Wed May 25, 10:53AM CDT
Santander Bank celebrated the relocation of one of its Manhattan branches today from the Flatiron District to a more visible and highly trafficked location just outside Union Square. The Bank marked the occasion with a $5,000 donation to the pioneering non-profit organization, Third Street Music School Settlement, the nation's longest-running community music school located just a few short blocks away from the branch in its new East Village neighborhood.
SAN: 4.21 (+0.25)
Why is Barclays (BCS) a Must Buy Foreign Bank Stock Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:18AM CDT
At a time when most foreign banks are struggling to regain foothold amid a challenging operating backdrop, Barclays is portraying a different picture. Let's check its strengths and the reasons to add this stock to your portfolio now.
BCS: 7.95 (+0.28), SAN: 4.21 (+0.25), BBVA: 5.82 (+0.24), ITUB: 9.76 (+0.02)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)
Santander Opens New Branch At Boston Medical Center
PR Newswire - Thu May 19, 10:53AM CDT
Santander Bank celebrated the opening of its newest Massachusetts branch at Boston Medical Center (BMC) today, furthering its commitment to the first-class healthcare facility. Executives and team members from Santander and BMC attended the grand opening and ribbon cutting to officially open the branch at 850 Harrison Avenue in Boston.
SAN: 4.21 (+0.25)
Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
BusinessWire - Mon May 16, 8:00AM CDT
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Sanofi Sends Letter to Medivation's Board of Directors
Globe Newswire - Thu May 05, 7:24AM CDT
Sanofi Sends Letter to Medivation's Board of Directors
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates
PR Newswire - Fri Apr 29, 6:37AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Kroll Bond Rating Agency Publishes Comment on U.S. Banks: Stress Tests & Quantitative Easing
BusinessWire - Tue Jul 05, 12:03PM CDT
Kroll Bond Rating Agency (KBRA) has released a new research report entitled "U.S. Banks: Stress Tests & Quantitative Easing." The report makes the following key points:
SAN: 4.21 (+0.25), DB: 14.10 (+0.80)
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
PR Newswire - Tue Jul 05, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)
Blow to Deutsche Bank, Santander: Fed Rejects Capital Plans
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 1:34PM CDT
The latest stress test results turned out to be continued embarrassments for Deutsche Bank AG (DB) and Banco Santander, S.A. (SAN) as the Federal Reserve objected to the capital plans of their U.S. units once again.
SAN: 4.21 (+0.25), C: 43.44 (+1.15), DB: 14.10 (+0.80), BAC: 13.54 (+0.33)
Statement on Results of the Federal Reserve's Comprehensive Capital Analysis and Review (CCAR)
PR Newswire - Wed Jun 29, 5:12PM CDT
The Board of Governors of the Federal Reserve System (Federal Reserve) disclosed today the results of its Comprehensive Capital Analysis and Review (CCAR). The results show that Santander Holdings USA, Inc.'s (SHUSA) capital ratios would be expected to remain significantly above minimum regulatory requirements under severely adverse economic stress scenarios.
SC: 11.24 (+0.42), SAN: 4.21 (+0.25)
Banco Santander Affirms 2016 Guidance amid Brexit Fallout
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:35AM CDT
Banco Santander does not expect Brexit to have a material impact on its profits in 2016.
SAN: 4.21 (+0.25), BMO: 64.33 (+0.83), V: 77.48 (+0.96), CM: 75.65 (+0.95)
New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire - Thu Jun 23, 6:56AM CDT
New VaxigripTetra(TM) vaccine:
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Watch List for Foreign Money Center Banks Equities -- Banco Santander, Barclays, Lloyds Banking Group, and Credit Suisse Group
PR Newswire - Wed Jun 15, 7:00AM CDT
On Tuesday, June 14, 2016, the NASDAQ Composite ended the trading session at 4,843.55, down 0.10%; the Dow Jones Industrial Average edged 0.33% lower to finish at 17,674.82; and the S&P 500 closed at 2,075.32, down 0.18%. Stock-Callers.com has initiated coverage on the following equities: Banco Santander S.A. (NYSE: SAN), Barclays PLC (NYSE: BCS), Lloyds Banking Group PLC (NYSE: LYG), and Credit Suisse Group A.G. (NYSE: CS). Learn more about these stocks by accessing their free trade alerts at:
BCS: 7.95 (+0.28), SAN: 4.21 (+0.25), CS: 11.07 (+0.31), LYG: 3.02 (+0.15)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
PR Newswire - Wed May 25, 5:50PM CDT
Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 (1 panelist did not vote due to travel) to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Santander Celebrates Branch Relocation To Union Square Area With Non-Profit Donation And Ribbon Cutting
PR Newswire - Wed May 25, 10:53AM CDT
Santander Bank celebrated the relocation of one of its Manhattan branches today from the Flatiron District to a more visible and highly trafficked location just outside Union Square. The Bank marked the occasion with a $5,000 donation to the pioneering non-profit organization, Third Street Music School Settlement, the nation's longest-running community music school located just a few short blocks away from the branch in its new East Village neighborhood.
SAN: 4.21 (+0.25)
Why is Barclays (BCS) a Must Buy Foreign Bank Stock Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:18AM CDT
At a time when most foreign banks are struggling to regain foothold amid a challenging operating backdrop, Barclays is portraying a different picture. Let's check its strengths and the reasons to add this stock to your portfolio now.
BCS: 7.95 (+0.28), SAN: 4.21 (+0.25), BBVA: 5.82 (+0.24), ITUB: 9.76 (+0.02)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08), REGN: 368.75 (-6.99)
Santander Opens New Branch At Boston Medical Center
PR Newswire - Thu May 19, 10:53AM CDT
Santander Bank celebrated the opening of its newest Massachusetts branch at Boston Medical Center (BMC) today, furthering its commitment to the first-class healthcare facility. Executives and team members from Santander and BMC attended the grand opening and ribbon cutting to officially open the branch at 850 Harrison Avenue in Boston.
SAN: 4.21 (+0.25)
Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
BusinessWire - Mon May 16, 8:00AM CDT
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Sanofi Sends Letter to Medivation's Board of Directors
Globe Newswire - Thu May 05, 7:24AM CDT
Sanofi Sends Letter to Medivation's Board of Directors
MDVN: 62.15 (-0.08), SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates
PR Newswire - Fri Apr 29, 6:37AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 4.21 (+0.25), SNY: 42.50 (+1.08)
